1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

(Shutterstock)
Key Takeaways
  • Small-cell lung cancer is an aggressive disease with few treatment options, but drug makers are looking to change that, with an eye toward combination treatments.

While significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?

 
• By Alaric DeArment

With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

AstraZeneca Scores FDA Win For Imfinzi In Perioperative Stomach Cancer

 
• By Alaric DeArment

The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.

Gilead Teams Up With Sweden’s Sprint For Latest Oncology Pact

 
• By Kevin Grogan

Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.

More from Business

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.